Clinical Trial

Gepant treAtments: EffectIveNess and tolERability (GAINER)

Study acronym: GAINER
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-06-05; most recent amendment 2026-01-19.
Status change: Not Yet Recruiting → Recruiting 2023-12-02
Trial Details
NCT Number NCT05903027
Lead Sponsor University of Florence
Collaborators: IRCCS National Neurological Institute "C. Mondino" Foundation, Società Italiana per lo Studio delle Cefalee, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Università degli Studi dell'Aquila, University of Roma La Sapienza, Azienda Ospedaliero Universitaria Policlinico Modena, Ospedale di Piove di Sacco, Azienda Ospedaliero-Universitaria di Parma, Azienda Ospedaliera S. Maria della Misericordia, A.O.U. Città della Salute e della Scienza, Cliniche Humanitas Gavazzeni, University of Campania Luigi Vanvitelli, Ospedale Santo Stefano, Azienda Policlinico Umberto I, Auxologico San Luca, Asst Degli Spedali Civili Di Brescia, Carlo Besta Neurological Institute
Conditions Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Enrollment 100 participants
Start Date 2023-06-15
Primary Completion 2024-06-15 (estimated)
Study Completion 2026-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-21